Key result
Up to 30% of patients admitted with pneumonia develop cardiovascular complications such as heart failure within 10 years of hospital discharge.
Why the study?
Pneumonia is an established contributing factor to major adverse cardiovascular events, and developing an intermechanistic understanding is crucial for successful future drug therapy and reducing healthcare expenditure.
Pneumonia is a significant contributor to major adverse cardiovascular events, highlighting the need for intermechanistic understanding to develop future drug therapies.
PURPOSE OF REVIEW: Pneumonia, an inflammatory disease, is the single largest infectious cause of death. Pneumonia has recently been established as an important contributing factor to major adverse cardiovascular events including heart failure. Developing an intermechanistic understanding of pneumonia and cardiovascular disease is crucial for successful future drug therapy and reducing healthcare expenditure. RECENT FINDINGS: Up to 30% of patients admitted with pneumonia develop cardiovascular complications such as heart failure within 10 years of hospital discharge. Recent mechanistic studies have identified inflammation, pneumolysin, platelet activation, and thrombus formation at the center of cardiovascular disease progression. SUMMARY: In this review, we will detail current knowledge of the mechanistic interaction between pneumonia and development of cardiovascular disease as well as discuss the current and potential drug therapy targets.
No takes yet. Share an insight, caveat, or question.
Bartlett et al. (2019) conducted a review in Pneumonia and cardiovascular disease. Pneumonia was evaluated on Cardiovascular complications (e.g., heart failure). Up to 30% of patients admitted with pneumonia develop cardiovascular complications such as heart failure within 10 years of hospital discharge.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: